Best Regional Bank Stocks For 2014

Until recently, I would have avoided regional banks. However, the green shoots of the U.S. recovery are now sturdy enough that select financial institutions are showing highly bullish charts backed by strong fundamentals. Both the technicals and fundamentals tell me there is a good trading opportunity at hand.

According to the Federal Deposit Insurance Corp. (FDIC), the number of bank failures has dropped dramatically since June 2011. At this time two years ago, 48 banks had entered receivership. By this time in 2012, the number dropped to 31. So far this year, only 16 banks have failed -- one-third the number of failures compared with 2011.

 

Moreover, revenue and earnings prospects for select regional banks should continue to improve. For starters, the Federal Reserve's pledge to keep interest rates near record lows means low-cost loans for consumers, and that translates to strong loan demand at banks. According to Reuters, demand for commercial and industrial loans is on the rise. Continued economic growth should spur consumer spending and further increase demand for loans.

5 Best Logistics Stocks To Buy Right Now: Liberty Property Trust (LRY)

Liberty Property Trust is a publicly owned real estate investment holding trust. Through its subsidiary, it provides leasing, property management, development, acquisition, and other tenant-related services for a portfolio of industrial and office properties. The firm invests in industrial properties including various warehouse, distribution, service, assembly, light manufacturing, and research and development facilities. Its office properties include multi-story and single-story office buildings located principally in suburban mixed-use developments or office parks. Liberty Property Trust was founded in 1972 and is based in Malvern, Pennsylvania.

Advisors' Opinion:

• [By Brad Thomas]

  Other REITs mentioned: (O), (NNN), (STAG), (DCT), (EGP), (PDM), (DRE), (LRY)

  Source: Chambers Street: More Liquidity Magic On The Way In REIT-Dom

  Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)

Best Regional Bank Stocks For 2014: IDGlobal Corp (IDGC)

ID Global Corporation (IDGC), incorporated on March 1, 2006, is a diversified holdings company with a focus on emerging and middle market investment opportunities in North America. The Company seeks to invest in emerging and private companies. The Company acts as a catalyst between the companies to raise and infuse capital when required.

The Company offers finance, social media and eco friendly products so that companies can independently manage and operate their business. IDGC through its debt and equity investments, controls interests in private companies, as well as special situation start-ups.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks IDGlobal Corp (OTCMKTS: IDGC), Embarr Downs Inc (OTCMKTS: EMBR) and SourcingLink.net, Inc (OTCMKTS: SNET) have been getting some extra attention in various investment newsletters or investor alerts lately as at least two of these stocks have been the subject of paid promotions or other types of investor relations activities. Of course, there is nothing wrong with properly disclosed promotions or investor relations activities. But just how hot are these two small cap stocks? Here is a closer look and a quick reality check:

Best Regional Bank Stocks For 2014: Rex Trueform Clothing Company Ltd (RTO)

Rex Trueform Clothing Company Limited is a South Africa-based company engaged in the manufacturing and marketing of clothing. The Company operates under two segments: Retail segment, the Company, through its ownership of Queenspark Limited, which operates a nationwide chain of Queenspark and J CREW stores, has a interest in the retailing of men�� and women�� clothing and related accessories. Through Property segment, Rex Trueform and its subsidiary have a direct investment in a portfolio of properties located in and around Cape Town. These properties are held either for the purpose of operations or for investment purposes. As of June 30, 2012, the Company operated 55 stores. In September 2012, the Company launched its newest brand Cath.Nic, a new fashion label exclusive to Queenspark. During the fiscal year ended June 30, 2012, the Company opened three new stores. Advisors' Opinion:

• [By Corinne Gretler]

  Rentokil Initial Plc (RTO) climbed 3.1 percent to 106 pence as Bank of America Corp. upgraded the U.K. pest-control and hygiene-services company to buy from neutral. The brokerage predicted that cash flow will improve in 2014 and 2015.

Best Regional Bank Stocks For 2014: Blackrock Corporate High Yield Fund Inc (HYT)

BlackRock Corporate High Yield Fund VI, Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income by investing primarily in a diversified portfolio of fixed-income securities.

The investments are rated in the lower rating categories of the rating services (Ba or lower by Moody's Investors Service, Inc., or BB or lower by Standard & Poor's Corporation) or are unrated securities of comparable quality. BlackRock Advisors, LLC. is the manager of the Fund.

Advisors' Opinion:

• [By Aaron Levitt]

  MMT comes with a hefty 6.76% distribution yield and is currently trading for a nearly 12% discount to its underlying value. That�� well over the normal discount range for the fund. �Expenses for MMT run 1.00% — or $100 per $10,000 invested — per year.

  BlackRock Corporate High Yield Fund (HYT)

  Discount to NAV: 7.11%
  Distribution Yield: 7.86%

Best Regional Bank Stocks For 2014: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors' Opinion:

• [By Ben Levisohn]

  Lower cholesterol means a higher price for Amgen’s (AMGN) stock–but could be bad news for Regeneron Pharmaceuticals (REGN).

  Shares of Amgen have gained 2% to $122.95 today after the biotech giant said that a trial showed it’s cholesterol drug works better than a placebo. Reuters has the details:

  Amgen Inc’s drug from a high profile new class of experimental medicines lowered “bad” LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday.

  Amgen had previously said the drug, evolocumab, met the main goals of five late-stage trials involving some 4,000 patients by significantly outperforming placebo or another cholesterol medicine in a variety of patient populations.

  Morgan Stanley’s Matthew Harrison and David Friedman note that the minimal number of “neurocognitive events” was good news for Amgen:

  Lack of neurocognitives could offer some relief, but overall data as expected. We would expect a modest uptick in A[Amgen] given the very clean data. That said, we believe the key debate continues to be around the long-term market size (which depends on CV outcomes) for which we do not have an answer. We found the data in HeFH and statin intolerant patients to be the most compelling given the high baseline LDL-C (~195mg/dL). We believe this population (~500k-1M) will see the most use prior to outcomes data given the higher unmet need.

  Credit Suisse analyst Jason Kantor and team call the results good news for Regeneron Pharmaceuticals version of the drug, but not necessarily its stock:

  Data from [Amgen's] evolocumab program substantially derisks the anti-PCSK9 drug class, demonstrating consistent efficacy and safety across multiple Phase III trials. Provided�[Regeneron] shows similar results (highly likely), competition is likely to focus on dosing strategy, while the ultimat

• [By Maxx Chatsko]

  3. Humira biosimilars
  What good is all the fear about generic versions, or biosimilars, of Humira if we never bring them out of the shadows? Who are these scary competitors? Four partnerships with programs under way stand out:

  AET BioTech and BioXpress Amgen (NASDAQ: AMGN  ) Boehringer Ingelheim Fujifilm Kyowa Kirin Biologics

  Efforts from Boehringer Ingelheim and Amgen would be the ones to watch. Amgen in particular is looking to biosimilars to provide a multibillion-dollar boost to its top line by the end of the decade. The biotech leader will launch six generic biologics by 2017, including one for the best-selling drug in the world. Not to discredit smaller companies with exceptional capabilities in biomanufacturing -- they tend to get overlooked as private firms -- but Amgen has a much broader reach financially and more experience with regulatory guidelines.

• [By Keith Speights]

  That's the message from Onyx Pharmaceuticals (NASDAQ: ONXX  ) over the weekend after Amgen (NASDAQ: AMGN  ) made an unsolicited offer to buy the company. Shares in Onyx jumped a whopping 51% higher on Monday following the company's decision to spurn the Amgen offer. Here's the full story.

Best Regional Bank Stocks For 2014: Tredegar Corporation(TG)

Tredegar Corporation, through its subsidiaries, manufactures and sells plastic films and aluminum extrusions worldwide. The company offers apertured film and nonwoven materials for use in feminine hygiene products, baby diapers, and adult incontinence products under the SoftQuilt, ComfortAire, SoftAire, and FreshFeel names; breathable, embossed, and elastic materials for use as components for baby diapers, adult incontinence products, and feminine hygiene products under the ExtraFlex, FabriFlex, StretchTab, FlexAire, and FlexFeel names; and absorbent transfer layers for baby diapers and adult incontinence products under the AquiDry and AquiSoft names. It also provides single and multi-layer surface protection films under the UltraMask and ForceField names for protecting components of flat panel displays; a line of packaging films for food packaging and industrial applications; and apertured films, breathable barrier films, and laminates that regulate fluid or vapor transmi ssion. In addition, the company offers soft-alloy aluminum extrusions primarily for building and construction, distribution, transportation, electrical, consumer durables, and machinery and equipment markets; and manufactures mill, anodized, and painted aluminum extrusions for fabricators and distributors to produce curtain walls, storefronts, windows and doors, hurricane shutters, tub and shower enclosures, heatsinks and components for light emitting diode (LED) lighting, and automotive and light truck aftermarket parts. Further, it develops and produces microstructure-based optical films for the LED and fluorescent lighting markets; and develops, owns, and operates mitigation banks. Tredegar Corporation was founded in 1988 and is headquartered in Richmond, Virginia.

Advisors' Opinion:

• [By Bryan Murphy]

  It's certainly not as big as Berry Plastics Group Inc. (NYSE:BERY). It's not even as big as Tredegar Corporation (NYSE:TG). There's one big way AEP Industries (NASDAQ:AEPI) can certainly compete head-on with BERY and TG right now, however... as an investment opportunity. Thanks to the bullish bump AEPI gave us last week, a long-standing selloff has been revered, and there's a whole lot of ground to make up.